Method for treating pulmonary arterial hypertension
AssigneeAGI Therapeutics Research Ltd.
InventorsJohn DEVANE, Jojn KELLY, Mary MARTIN
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats, prevents and/or manages at least one condition having MT1 receptor, 5-HT2B receptor and L-type calcium channel activity and releases the (R)-verapamil, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a co-primary activity on the MT1 receptor, the 5-HT2B receptor, and the L-type calcium channel.
Claims17
A method for treating pulmonary arterial hypertension in a subject comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, or a pharmaceutically acceptable salt thereof, wherein the composition releases the (R)-verapamil, or a pharmaceutically acceptable salt thereof, in the subject to exhibit a co-primary activity on the melatonin (“MT1”) receptor, the 5-hydroxytryptamine type 2B (“5-HT2B”) receptor, and the L-type calcium channel to thereby treat the pulmonary arterial hypertension.
-5. (canceled)
-13. (canceled)
A method for managing pulmonary arterial hypertension in a subject comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil or a pharmaceutically acceptable salt thereof, wherein the composition releases the (R)-verapamil, or a pharmaceutically acceptable salt thereof, in the subject to exhibit a co-primary activity on the MT1 receptor, the 5-HT2B receptor, and the L-type calcium channel to thereby manage the pulmonary arterial hypertension.
-26. (canceled)
Dependencies are inferred from the claim text.